Open Access

Primary extra‑nodal diffuse large B‑cell lymphoma: A prognostic analysis of 141 patients

  • Authors:
    • Haorui Shen
    • Zhang Wei
    • Daobin Zhou
    • Yan Zhang
    • Xiao Han
    • Wei Wang
    • Lu Zhang
    • Chen Yang
    • Jun Feng
  • View Affiliations

  • Published online on: May 24, 2018     https://doi.org/10.3892/ol.2018.8803
  • Pages: 1602-1614
  • Copyright: © Shen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Diffuse large B‑cell lymphoma (DLBCL) is the most common subtype of lymphoma. Approximately 40% of DBLCL originates from extra‑nodal sites, but the diversity of clinical presentations and the genetic and molecular alterations indicate that extra‑nodal DLBCLs may be distinct disease entities. The aim of the present study was to highlight the various aspects of primary extra‑nodal DLBCL (PE‑DLBCL) based on a single center cohort. The data from 141 patients with PE‑DLBCL treated at Peking Union Medical College Hospital were retrospectively evaluated. The primary extra‑nodal sites involved were the gastrointestinal tract (n=42), central nervous system (CNS; n=38), breast (n=19), adrenal gland (n=15), female genital system (FGS; n=12), thyroid (n=8) and bone (n=7). The median overall survival rate was 28 months (range, 1‑116). Multivariate analysis demonstrated that an International Prognostic Index (IPI) ≤2 (P=0.049), complete remission (CR) achieved following first‑line therapy (P=0.001) and chemotherapy combined with rituximab (P<0.001) were positive prognostic factors. Patients with DLBCL with primary adrenal gland or female genital system (FGS) involvement exhibited a significantly higher risk of CNS recurrence (P<0.05). Rituximab treatment may have reduced the likelihood of CNS recurrence (P=0.005), whereas prophylaxis with intrathecal injection alone was not sufficient for prevention (P>0.05). In conclusion, IPI >2 and the lack of a CR following first‑line therapy were independent prognostic risk factors for PE‑DLBCL. Patients with primary adrenal gland or FGS involvement exhibited a higher risk of CNS relapse. Rituximab had a positive impact on the survival of patients with PE‑DLBCL, also reducing the likelihood of CNS relapse.
View Figures
View References

Related Articles

Journal Cover

August-2018
Volume 16 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Shen H, Wei Z, Zhou D, Zhang Y, Han X, Wang W, Zhang L, Yang C and Feng J: Primary extra‑nodal diffuse large B‑cell lymphoma: A prognostic analysis of 141 patients. Oncol Lett 16: 1602-1614, 2018
APA
Shen, H., Wei, Z., Zhou, D., Zhang, Y., Han, X., Wang, W. ... Feng, J. (2018). Primary extra‑nodal diffuse large B‑cell lymphoma: A prognostic analysis of 141 patients. Oncology Letters, 16, 1602-1614. https://doi.org/10.3892/ol.2018.8803
MLA
Shen, H., Wei, Z., Zhou, D., Zhang, Y., Han, X., Wang, W., Zhang, L., Yang, C., Feng, J."Primary extra‑nodal diffuse large B‑cell lymphoma: A prognostic analysis of 141 patients". Oncology Letters 16.2 (2018): 1602-1614.
Chicago
Shen, H., Wei, Z., Zhou, D., Zhang, Y., Han, X., Wang, W., Zhang, L., Yang, C., Feng, J."Primary extra‑nodal diffuse large B‑cell lymphoma: A prognostic analysis of 141 patients". Oncology Letters 16, no. 2 (2018): 1602-1614. https://doi.org/10.3892/ol.2018.8803